{"schema_version":"secwatch.filing_event.v1","accession":"0001607062-22-000495","form_type":"8-K","ticker":"RGBP","cik":"0001589150","company_name":"Regen BioPharma Inc","filed_at":"2022-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.275486+00:00","generated_at":"2026-06-24T01:25:37.339488+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Regen Biopharma subsidiary files provisional patent for CAR T-cell dedifferentiation method","bullets":["KCL Therapeutics, a wholly owned subsidiary, filed a provisional patent application with USPTO on August 9, 2022.","Patent covers methods, means and compositions for enhancing antitumor activity of CAR T cells through dedifferentiation.","CAR T cells are modified immune T cells that attack cancer-specific antigens; developed from bone marrow stem cells.","Provisional application marks initial step in securing IP for this cancer treatment approach."],"urls":{"canonical":"https://secwatch.observer/filing/0001607062-22-000495","json":"https://secwatch.observer/filing/0001607062-22-000495.json","markdown":"https://secwatch.observer/filing/0001607062-22-000495.md","text":"https://secwatch.observer/filing/0001607062-22-000495.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1589150/000160706222000495/0001607062-22-000495-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1589150/000160706222000495/rgbp080922form8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T01:25:37.339488+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}